Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A
Autor*in: |
Kowanetz, Marcin [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2014 |
---|
Schlagwörter: |
---|
Anmerkung: |
© Kowanetz et al.; licensee BioMed Central Ltd. 2014 |
---|
Übergeordnetes Werk: |
Enthalten in: Journal for ImmunoTherapy of Cancer - London : BioMed Central, 2013, 2(2014), Suppl 3 vom: 06. Nov. |
---|---|
Übergeordnetes Werk: |
volume:2 ; year:2014 ; number:Suppl 3 ; day:06 ; month:11 |
Links: |
---|
DOI / URN: |
10.1186/2051-1426-2-S3-P136 |
---|
Katalog-ID: |
SPR036426636 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR036426636 | ||
003 | DE-627 | ||
005 | 20230519072002.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2014 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/2051-1426-2-S3-P136 |2 doi | |
035 | |a (DE-627)SPR036426636 | ||
035 | |a (SPR)2051-1426-2-S3-P136-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kowanetz, Marcin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A |
264 | 1 | |c 2014 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Kowanetz et al.; licensee BioMed Central Ltd. 2014 | ||
650 | 4 | |a Immune Checkpoint |7 (dpeaa)DE-He213 | |
650 | 4 | |a Checkpoint Inhibition |7 (dpeaa)DE-He213 | |
650 | 4 | |a Cell Alpha |7 (dpeaa)DE-He213 | |
650 | 4 | |a Immune Checkpoint Inhibition |7 (dpeaa)DE-He213 | |
650 | 4 | |a Multiple Tumor Type |7 (dpeaa)DE-He213 | |
700 | 1 | |a Rabe, Christina |4 aut | |
700 | 1 | |a Xiao, Yuanyuan |4 aut | |
700 | 1 | |a Wu, Qun J |4 aut | |
700 | 1 | |a Koeppen, Hartmut |4 aut | |
700 | 1 | |a Leddy, Cecilia |4 aut | |
700 | 1 | |a Patel, Rajesh D |4 aut | |
700 | 1 | |a Powderly, John |4 aut | |
700 | 1 | |a Kohrt, Holbrook |4 aut | |
700 | 1 | |a Gettinger, Scott |4 aut | |
700 | 1 | |a Soria, Jean-Charles |4 aut | |
700 | 1 | |a Herbst, Roy S |4 aut | |
700 | 1 | |a Desai, Rupal |4 aut | |
700 | 1 | |a Denker, Mitchell |4 aut | |
700 | 1 | |a Ruppel, Jane |4 aut | |
700 | 1 | |a Boe, Marigold |4 aut | |
700 | 1 | |a Nakamura, Rin |4 aut | |
700 | 1 | |a Fu, Ling |4 aut | |
700 | 1 | |a Sumiyoshi, Teiko |4 aut | |
700 | 1 | |a Mokatrin, Ahmad |4 aut | |
700 | 1 | |a Shen, Xiaodong |4 aut | |
700 | 1 | |a Fine, Gregg |4 aut | |
700 | 1 | |a Chen, Daniel S |4 aut | |
700 | 1 | |a Hegde, Priti S |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal for ImmunoTherapy of Cancer |d London : BioMed Central, 2013 |g 2(2014), Suppl 3 vom: 06. Nov. |w (DE-627)750086335 |w (DE-600)2719863-7 |x 2051-1426 |7 nnns |
773 | 1 | 8 | |g volume:2 |g year:2014 |g number:Suppl 3 |g day:06 |g month:11 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/2051-1426-2-S3-P136 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 2 |j 2014 |e Suppl 3 |b 06 |c 11 |
author_variant |
m k mk c r cr y x yx q j w qj qjw h k hk c l cl r d p rd rdp j p jp h k hk s g sg j c s jcs r s h rs rsh r d rd m d md j r jr m b mb r n rn l f lf t s ts a m am x s xs g f gf d s c ds dsc p s h ps psh |
---|---|
matchkey_str |
article:20511426:2014----::icltnaduobsdimresrdcciiaatvticneptettetdihheg |
hierarchy_sort_str |
2014 |
publishDate |
2014 |
allfields |
10.1186/2051-1426-2-S3-P136 doi (DE-627)SPR036426636 (SPR)2051-1426-2-S3-P136-e DE-627 ger DE-627 rakwb eng Kowanetz, Marcin verfasserin aut Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Kowanetz et al.; licensee BioMed Central Ltd. 2014 Immune Checkpoint (dpeaa)DE-He213 Checkpoint Inhibition (dpeaa)DE-He213 Cell Alpha (dpeaa)DE-He213 Immune Checkpoint Inhibition (dpeaa)DE-He213 Multiple Tumor Type (dpeaa)DE-He213 Rabe, Christina aut Xiao, Yuanyuan aut Wu, Qun J aut Koeppen, Hartmut aut Leddy, Cecilia aut Patel, Rajesh D aut Powderly, John aut Kohrt, Holbrook aut Gettinger, Scott aut Soria, Jean-Charles aut Herbst, Roy S aut Desai, Rupal aut Denker, Mitchell aut Ruppel, Jane aut Boe, Marigold aut Nakamura, Rin aut Fu, Ling aut Sumiyoshi, Teiko aut Mokatrin, Ahmad aut Shen, Xiaodong aut Fine, Gregg aut Chen, Daniel S aut Hegde, Priti S aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 2(2014), Suppl 3 vom: 06. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:2 year:2014 number:Suppl 3 day:06 month:11 https://dx.doi.org/10.1186/2051-1426-2-S3-P136 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2014 Suppl 3 06 11 |
spelling |
10.1186/2051-1426-2-S3-P136 doi (DE-627)SPR036426636 (SPR)2051-1426-2-S3-P136-e DE-627 ger DE-627 rakwb eng Kowanetz, Marcin verfasserin aut Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Kowanetz et al.; licensee BioMed Central Ltd. 2014 Immune Checkpoint (dpeaa)DE-He213 Checkpoint Inhibition (dpeaa)DE-He213 Cell Alpha (dpeaa)DE-He213 Immune Checkpoint Inhibition (dpeaa)DE-He213 Multiple Tumor Type (dpeaa)DE-He213 Rabe, Christina aut Xiao, Yuanyuan aut Wu, Qun J aut Koeppen, Hartmut aut Leddy, Cecilia aut Patel, Rajesh D aut Powderly, John aut Kohrt, Holbrook aut Gettinger, Scott aut Soria, Jean-Charles aut Herbst, Roy S aut Desai, Rupal aut Denker, Mitchell aut Ruppel, Jane aut Boe, Marigold aut Nakamura, Rin aut Fu, Ling aut Sumiyoshi, Teiko aut Mokatrin, Ahmad aut Shen, Xiaodong aut Fine, Gregg aut Chen, Daniel S aut Hegde, Priti S aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 2(2014), Suppl 3 vom: 06. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:2 year:2014 number:Suppl 3 day:06 month:11 https://dx.doi.org/10.1186/2051-1426-2-S3-P136 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2014 Suppl 3 06 11 |
allfields_unstemmed |
10.1186/2051-1426-2-S3-P136 doi (DE-627)SPR036426636 (SPR)2051-1426-2-S3-P136-e DE-627 ger DE-627 rakwb eng Kowanetz, Marcin verfasserin aut Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Kowanetz et al.; licensee BioMed Central Ltd. 2014 Immune Checkpoint (dpeaa)DE-He213 Checkpoint Inhibition (dpeaa)DE-He213 Cell Alpha (dpeaa)DE-He213 Immune Checkpoint Inhibition (dpeaa)DE-He213 Multiple Tumor Type (dpeaa)DE-He213 Rabe, Christina aut Xiao, Yuanyuan aut Wu, Qun J aut Koeppen, Hartmut aut Leddy, Cecilia aut Patel, Rajesh D aut Powderly, John aut Kohrt, Holbrook aut Gettinger, Scott aut Soria, Jean-Charles aut Herbst, Roy S aut Desai, Rupal aut Denker, Mitchell aut Ruppel, Jane aut Boe, Marigold aut Nakamura, Rin aut Fu, Ling aut Sumiyoshi, Teiko aut Mokatrin, Ahmad aut Shen, Xiaodong aut Fine, Gregg aut Chen, Daniel S aut Hegde, Priti S aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 2(2014), Suppl 3 vom: 06. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:2 year:2014 number:Suppl 3 day:06 month:11 https://dx.doi.org/10.1186/2051-1426-2-S3-P136 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2014 Suppl 3 06 11 |
allfieldsGer |
10.1186/2051-1426-2-S3-P136 doi (DE-627)SPR036426636 (SPR)2051-1426-2-S3-P136-e DE-627 ger DE-627 rakwb eng Kowanetz, Marcin verfasserin aut Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Kowanetz et al.; licensee BioMed Central Ltd. 2014 Immune Checkpoint (dpeaa)DE-He213 Checkpoint Inhibition (dpeaa)DE-He213 Cell Alpha (dpeaa)DE-He213 Immune Checkpoint Inhibition (dpeaa)DE-He213 Multiple Tumor Type (dpeaa)DE-He213 Rabe, Christina aut Xiao, Yuanyuan aut Wu, Qun J aut Koeppen, Hartmut aut Leddy, Cecilia aut Patel, Rajesh D aut Powderly, John aut Kohrt, Holbrook aut Gettinger, Scott aut Soria, Jean-Charles aut Herbst, Roy S aut Desai, Rupal aut Denker, Mitchell aut Ruppel, Jane aut Boe, Marigold aut Nakamura, Rin aut Fu, Ling aut Sumiyoshi, Teiko aut Mokatrin, Ahmad aut Shen, Xiaodong aut Fine, Gregg aut Chen, Daniel S aut Hegde, Priti S aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 2(2014), Suppl 3 vom: 06. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:2 year:2014 number:Suppl 3 day:06 month:11 https://dx.doi.org/10.1186/2051-1426-2-S3-P136 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2014 Suppl 3 06 11 |
allfieldsSound |
10.1186/2051-1426-2-S3-P136 doi (DE-627)SPR036426636 (SPR)2051-1426-2-S3-P136-e DE-627 ger DE-627 rakwb eng Kowanetz, Marcin verfasserin aut Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Kowanetz et al.; licensee BioMed Central Ltd. 2014 Immune Checkpoint (dpeaa)DE-He213 Checkpoint Inhibition (dpeaa)DE-He213 Cell Alpha (dpeaa)DE-He213 Immune Checkpoint Inhibition (dpeaa)DE-He213 Multiple Tumor Type (dpeaa)DE-He213 Rabe, Christina aut Xiao, Yuanyuan aut Wu, Qun J aut Koeppen, Hartmut aut Leddy, Cecilia aut Patel, Rajesh D aut Powderly, John aut Kohrt, Holbrook aut Gettinger, Scott aut Soria, Jean-Charles aut Herbst, Roy S aut Desai, Rupal aut Denker, Mitchell aut Ruppel, Jane aut Boe, Marigold aut Nakamura, Rin aut Fu, Ling aut Sumiyoshi, Teiko aut Mokatrin, Ahmad aut Shen, Xiaodong aut Fine, Gregg aut Chen, Daniel S aut Hegde, Priti S aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 2(2014), Suppl 3 vom: 06. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:2 year:2014 number:Suppl 3 day:06 month:11 https://dx.doi.org/10.1186/2051-1426-2-S3-P136 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2014 Suppl 3 06 11 |
language |
English |
source |
Enthalten in Journal for ImmunoTherapy of Cancer 2(2014), Suppl 3 vom: 06. Nov. volume:2 year:2014 number:Suppl 3 day:06 month:11 |
sourceStr |
Enthalten in Journal for ImmunoTherapy of Cancer 2(2014), Suppl 3 vom: 06. Nov. volume:2 year:2014 number:Suppl 3 day:06 month:11 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Immune Checkpoint Checkpoint Inhibition Cell Alpha Immune Checkpoint Inhibition Multiple Tumor Type |
isfreeaccess_bool |
true |
container_title |
Journal for ImmunoTherapy of Cancer |
authorswithroles_txt_mv |
Kowanetz, Marcin @@aut@@ Rabe, Christina @@aut@@ Xiao, Yuanyuan @@aut@@ Wu, Qun J @@aut@@ Koeppen, Hartmut @@aut@@ Leddy, Cecilia @@aut@@ Patel, Rajesh D @@aut@@ Powderly, John @@aut@@ Kohrt, Holbrook @@aut@@ Gettinger, Scott @@aut@@ Soria, Jean-Charles @@aut@@ Herbst, Roy S @@aut@@ Desai, Rupal @@aut@@ Denker, Mitchell @@aut@@ Ruppel, Jane @@aut@@ Boe, Marigold @@aut@@ Nakamura, Rin @@aut@@ Fu, Ling @@aut@@ Sumiyoshi, Teiko @@aut@@ Mokatrin, Ahmad @@aut@@ Shen, Xiaodong @@aut@@ Fine, Gregg @@aut@@ Chen, Daniel S @@aut@@ Hegde, Priti S @@aut@@ |
publishDateDaySort_date |
2014-11-06T00:00:00Z |
hierarchy_top_id |
750086335 |
id |
SPR036426636 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036426636</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519072002.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/2051-1426-2-S3-P136</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036426636</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)2051-1426-2-S3-P136-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kowanetz, Marcin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Kowanetz et al.; licensee BioMed Central Ltd. 2014</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune Checkpoint</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Checkpoint Inhibition</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cell Alpha</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune Checkpoint Inhibition</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Tumor Type</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rabe, Christina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiao, Yuanyuan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Qun J</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koeppen, Hartmut</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leddy, Cecilia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patel, Rajesh D</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Powderly, John</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohrt, Holbrook</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gettinger, Scott</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Soria, Jean-Charles</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herbst, Roy S</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Desai, Rupal</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Denker, Mitchell</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ruppel, Jane</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boe, Marigold</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakamura, Rin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fu, Ling</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sumiyoshi, Teiko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mokatrin, Ahmad</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shen, Xiaodong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fine, Gregg</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Daniel S</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hegde, Priti S</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal for ImmunoTherapy of Cancer</subfield><subfield code="d">London : BioMed Central, 2013</subfield><subfield code="g">2(2014), Suppl 3 vom: 06. Nov.</subfield><subfield code="w">(DE-627)750086335</subfield><subfield code="w">(DE-600)2719863-7</subfield><subfield code="x">2051-1426</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:Suppl 3</subfield><subfield code="g">day:06</subfield><subfield code="g">month:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/2051-1426-2-S3-P136</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2014</subfield><subfield code="e">Suppl 3</subfield><subfield code="b">06</subfield><subfield code="c">11</subfield></datafield></record></collection>
|
author |
Kowanetz, Marcin |
spellingShingle |
Kowanetz, Marcin misc Immune Checkpoint misc Checkpoint Inhibition misc Cell Alpha misc Immune Checkpoint Inhibition misc Multiple Tumor Type Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A |
authorStr |
Kowanetz, Marcin |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)750086335 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
2051-1426 |
topic_title |
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A Immune Checkpoint (dpeaa)DE-He213 Checkpoint Inhibition (dpeaa)DE-He213 Cell Alpha (dpeaa)DE-He213 Immune Checkpoint Inhibition (dpeaa)DE-He213 Multiple Tumor Type (dpeaa)DE-He213 |
topic |
misc Immune Checkpoint misc Checkpoint Inhibition misc Cell Alpha misc Immune Checkpoint Inhibition misc Multiple Tumor Type |
topic_unstemmed |
misc Immune Checkpoint misc Checkpoint Inhibition misc Cell Alpha misc Immune Checkpoint Inhibition misc Multiple Tumor Type |
topic_browse |
misc Immune Checkpoint misc Checkpoint Inhibition misc Cell Alpha misc Immune Checkpoint Inhibition misc Multiple Tumor Type |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Journal for ImmunoTherapy of Cancer |
hierarchy_parent_id |
750086335 |
hierarchy_top_title |
Journal for ImmunoTherapy of Cancer |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)750086335 (DE-600)2719863-7 |
title |
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A |
ctrlnum |
(DE-627)SPR036426636 (SPR)2051-1426-2-S3-P136-e |
title_full |
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A |
author_sort |
Kowanetz, Marcin |
journal |
Journal for ImmunoTherapy of Cancer |
journalStr |
Journal for ImmunoTherapy of Cancer |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2014 |
contenttype_str_mv |
txt |
author_browse |
Kowanetz, Marcin Rabe, Christina Xiao, Yuanyuan Wu, Qun J Koeppen, Hartmut Leddy, Cecilia Patel, Rajesh D Powderly, John Kohrt, Holbrook Gettinger, Scott Soria, Jean-Charles Herbst, Roy S Desai, Rupal Denker, Mitchell Ruppel, Jane Boe, Marigold Nakamura, Rin Fu, Ling Sumiyoshi, Teiko Mokatrin, Ahmad Shen, Xiaodong Fine, Gregg Chen, Daniel S Hegde, Priti S |
container_volume |
2 |
format_se |
Elektronische Aufsätze |
author-letter |
Kowanetz, Marcin |
doi_str_mv |
10.1186/2051-1426-2-S3-P136 |
title_sort |
circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-pd-l1 antibody mpdl3280a |
title_auth |
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A |
abstract |
© Kowanetz et al.; licensee BioMed Central Ltd. 2014 |
abstractGer |
© Kowanetz et al.; licensee BioMed Central Ltd. 2014 |
abstract_unstemmed |
© Kowanetz et al.; licensee BioMed Central Ltd. 2014 |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
Suppl 3 |
title_short |
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A |
url |
https://dx.doi.org/10.1186/2051-1426-2-S3-P136 |
remote_bool |
true |
author2 |
Rabe, Christina Xiao, Yuanyuan Wu, Qun J Koeppen, Hartmut Leddy, Cecilia Patel, Rajesh D Powderly, John Kohrt, Holbrook Gettinger, Scott Soria, Jean-Charles Herbst, Roy S Desai, Rupal Denker, Mitchell Ruppel, Jane Boe, Marigold Nakamura, Rin Fu, Ling Sumiyoshi, Teiko Mokatrin, Ahmad Shen, Xiaodong Fine, Gregg Chen, Daniel S Hegde, Priti S |
author2Str |
Rabe, Christina Xiao, Yuanyuan Wu, Qun J Koeppen, Hartmut Leddy, Cecilia Patel, Rajesh D Powderly, John Kohrt, Holbrook Gettinger, Scott Soria, Jean-Charles Herbst, Roy S Desai, Rupal Denker, Mitchell Ruppel, Jane Boe, Marigold Nakamura, Rin Fu, Ling Sumiyoshi, Teiko Mokatrin, Ahmad Shen, Xiaodong Fine, Gregg Chen, Daniel S Hegde, Priti S |
ppnlink |
750086335 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/2051-1426-2-S3-P136 |
up_date |
2024-07-03T17:33:01.955Z |
_version_ |
1803580061209591808 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036426636</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519072002.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/2051-1426-2-S3-P136</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036426636</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)2051-1426-2-S3-P136-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kowanetz, Marcin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Kowanetz et al.; licensee BioMed Central Ltd. 2014</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune Checkpoint</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Checkpoint Inhibition</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cell Alpha</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune Checkpoint Inhibition</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Tumor Type</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rabe, Christina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiao, Yuanyuan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Qun J</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koeppen, Hartmut</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leddy, Cecilia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patel, Rajesh D</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Powderly, John</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohrt, Holbrook</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gettinger, Scott</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Soria, Jean-Charles</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herbst, Roy S</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Desai, Rupal</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Denker, Mitchell</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ruppel, Jane</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boe, Marigold</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakamura, Rin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fu, Ling</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sumiyoshi, Teiko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mokatrin, Ahmad</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shen, Xiaodong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fine, Gregg</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Daniel S</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hegde, Priti S</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal for ImmunoTherapy of Cancer</subfield><subfield code="d">London : BioMed Central, 2013</subfield><subfield code="g">2(2014), Suppl 3 vom: 06. Nov.</subfield><subfield code="w">(DE-627)750086335</subfield><subfield code="w">(DE-600)2719863-7</subfield><subfield code="x">2051-1426</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:Suppl 3</subfield><subfield code="g">day:06</subfield><subfield code="g">month:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/2051-1426-2-S3-P136</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2014</subfield><subfield code="e">Suppl 3</subfield><subfield code="b">06</subfield><subfield code="c">11</subfield></datafield></record></collection>
|
score |
7.3993607 |